This study evaluated the potential for use of circulating concentrations of MMP-2, MMP-9, TIMP-1, and TIMP-2 as diagnostic markers for endoleak or treatment of AAA by EVAR. This evidence concerns the gene MMP9 and triple-A syndrome.